Want to see IN:SOLARA full AI Analyst Report?
SOLARA Stock Chart & Stats
₹490.35
₹13.05(2.65%)
At close: 4:00 PM EDT
₹490.35
₹13.05(2.65%)
Day’s Range― - ―
52-Week Range₹422.85 - ₹711.20
Previous CloseN/A
Volume579.03K
Average Volume (3M)37.94K
Market Cap
₹30.03B
Enterprise Value₹33.31K
Total Cash (Recent Filing)₹533.40M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Nov 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.56
Shares Outstanding47,794,580
10 Day Avg. Volume26,889
30 Day Avg. Volume37,944
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.50
Price to Sales (P/S)1.37
P/FCF Ratio211.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)31.4
Revenue Forecast (FY)₹17.95B
Bulls Say, Bears Say
Bulls Say
Revenue RecoveryFY2026 revenue returned to 13.5% growth after a flat FY2025, indicating demand and commercial activity regained traction. Sustained growth could improve absorption of the API manufacturing base and support earnings recovery.
Improving LeverageDebt-to-equity fell from about 1.08x in FY2024 to 0.55x in FY2026 as equity increased and debt declined. This improves financial flexibility and reduces balance-sheet risk during periods of earnings volatility.
Global API And CDMO PlatformSolara's API manufacturing and CDMO model serves pharmaceutical customers across regulated and semi-regulated markets. Repeat supply relationships, regulatory capabilities and export reach can support durable customer retention and diversified demand.
Bears Say
Persistent Net LossDespite operating improvement, Solara remained loss-making at the net level in FY2026 and generated negative shareholder returns. Continued losses could constrain internally funded investment and weaken confidence in sustainable earnings power.
Gross Margin VolatilityThe sharp gross-margin swing suggests ongoing exposure to pricing, product-mix or input-cost changes. Such volatility makes earnings less predictable and may limit the durability of operating-profit recovery without better cost and mix stability.
Weakening Cash GenerationCash generation remained positive but deteriorated materially, with free cash flow down about 80% year over year. Lower cash conversion may reflect weaker underlying profitability or working-capital pressure, reducing funds available for growth and debt service.
Solara Active Pharma Sciences Ltd. News
SOLARA FAQ
What was Solara Active Pharma Sciences Ltd.’s price range in the past 12 months?
Solara Active Pharma Sciences Ltd. lowest stock price was ₹422.85 and its highest was ₹711.20 in the past 12 months.
What is Solara Active Pharma Sciences Ltd.’s market cap?
Solara Active Pharma Sciences Ltd.’s market cap is ₹30.03B.
When is Solara Active Pharma Sciences Ltd.’s upcoming earnings report date?
Solara Active Pharma Sciences Ltd.’s upcoming earnings report date is Nov 11, 2026 which is in 77 days.
How were Solara Active Pharma Sciences Ltd.’s earnings last quarter?
Solara Active Pharma Sciences Ltd. released its earnings results on Jul 23, 2026. The company reported ₹3.52 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Solara Active Pharma Sciences Ltd. overvalued?
According to Wall Street analysts Solara Active Pharma Sciences Ltd.’s price is currently Overvalued.
Does Solara Active Pharma Sciences Ltd. pay dividends?
Solara Active Pharma Sciences Ltd. pays a Notavailable dividend of ₹3 which represents an annual dividend yield of N/A. See more information on Solara Active Pharma Sciences Ltd. dividends here
What is Solara Active Pharma Sciences Ltd.’s EPS estimate?
Solara Active Pharma Sciences Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Solara Active Pharma Sciences Ltd. have?
Solara Active Pharma Sciences Ltd. has 47,794,580 shares outstanding.
What happened to Solara Active Pharma Sciences Ltd.’s price movement after its last earnings report?
Solara Active Pharma Sciences Ltd. reported an EPS of ₹3.52 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.12%.
Which hedge fund is a major shareholder of Solara Active Pharma Sciences Ltd.?
Currently, no hedge funds are holding shares in IN:SOLARA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Solara Active Pharma Sciences Ltd.
Solara Active Pharma Sciences Limited is an Indian-based pharmaceutical company primarily involved in the comprehensive development, production, and global trade of active pharmaceutical ingredients (APIs). Their activities span the manufacturing, processing, sale, import, and export of these essential drug components. The company's extensive product range includes APIs designed for a wide spectrum of therapeutic applications, such as anesthetics, antibiotics, antivirals, cardiovascular agents, central nervous system treatments, anti-inflammatory drugs, and treatments for metabolic disorders like type-II diabetes, among numerous other specialized categories. Beyond its core product offerings, Solara also delivers specialized contract research and manufacturing services (CRAMS) for APIs. These services encompass custom development and manufacturing, analytical support, impurity synthesis, and comprehensive regulatory assistance. The company maintains a significant international presence, exporting its products and conducting operations across diverse global regions, including the Asia Pacific, Europe, North America, and South America. Headquartered in Chennai, India, Solara Active Pharma Sciences Limited was established in 2017. Initially known as SSL Pharma Sciences Limited, the company adopted its current name in March of the same year.
Technical Analysis
Granules India Limited
―
Hikal Limited
―
IOL Chemicals & Pharmaceuticals Ltd.
―
Strides Pharma Science Ltd
―
Unichem Laboratories Limited
―